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Summary. The limited and inadequate availability of
organs from human donors has resulted in the utilisation
of xenografts as an alternative tool. Nevertheless,
hyperacute rejection (HAR) following xenograft
determines the loss of the transplanted organ. The
“primum movens” is the activation of the complement
pathway mediated by the binding of natural xenogenic
antibodies to the endothelium of the graft, followed by
the lysis of the endothelial cells with subsequent
oedema, thrombosis and necrosis of the transplanted
organ. In this work we describe morphological and
biomolecular observations of isolated human-decay
accelerating factor (h-DAF, CD55) transgenic pig hearts,
after perfusion for four hours with human blood. H-DAF
is a membrane glycoprotein inhibiting the complement
activation in humans. We describe considerably reduced
damages in transgenic hearts, compared to controls. The
cardiac function resulted preserved. Our data are in
agreement with what was already shown by other groups
using different experimental models. In conclusion, we
encourage the use of new sources of transgenic animals,
pointing out the importance of morphological analysis in
evaluation of xenograft.
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Introduction
Recent advances in surgical techniques and modern
immunosuppressive therapies have increased the
demand for organ transplantation. The lack of donors has
encouraged the utilisation of animals as a potential
source of organs (Calne, 1970). The main obstacle for
this procedure, called xenograft, is the hyperacute
rejection (HAR) that arises in the transplanted organs;
this is characterised by vascular endothelium
destruction, massive interstitial oedema, haemorrhage
and necrosis (Platt and Bach 1991). The transplanted
organs do not show the same sensitivity for HAR. Heart
and kidney undergo an early and serious damage, while
liver and skin show a greater resistance to this
phenomenon. The cause for this different behaviour is
still not clear (Bach et al., 1995). 
The histopathological features of HAR are the
consequence of an immediate and aggressive
immunological response, in which preformed circulating
antibodies, present in the host, bind to specific graft
endothelial antigens and activate the complement system
(Hammond, 1989). Briefly, the events of the
complement cascade consist of a specific sequence of
proteolytic steps, in which inactive precursor proteins
are cleaved to yield a large and a small fragment. The
former binds to the host cell surface and contributes to
the following proteolytic cleavage; the latter often
mediates the inflammatory response. 
A critical step in the complement sequence is the
production of a protease, called C3 convertase, which
determines the activation of the complement component
3 (C3). This protein is the first component shared by
both the classical and alternative pathways and its
cleavage generates the most important mediators of the
complement system. In particular, its cleavage
determines the production of the two mediators, C3a and
C3b. The latter is subsequently cleaved in another two
fragments, C3c and C3d. These peptides are deposited in
large quantities on the host cell surface, representing an
inflammatory stimulus and triggering the late events of
the complement cascade (Janeway and Travers, 
1997a). 
Specific proteins regulate the complement pathway,
such as CD46 (Membrane Cofactor Protein, MCP),
CD55 (Decay Accelerating Factor, DAF) and CD59
(Homologous Restriction Factor, HRF); they act
specifically, protecting the cells from accidental damage.
In particular, human-DAF (h-DAF) lays on the surface
of blood and endothelial cells, where it acts by
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dissociating specific complement catalytic subunits and
preventing the progression of this pathway (Janeway and
Travers, 1997a). Since these complement regulatory
proteins show a high species specificity, their presence
on animal endothelial cells can not protect transplanted
organs from the attack of human complement (Hansch et
al., 1981; van der Berg and Morgan, 1994). Therefore,
organs from transgenic animals expressing human
proteins like CD46, CD55 and CD59 undergo a limited
damage caused by HAR in xenografts (McCurry 1995a;
Schmoeckel et al., 1996, 1997). 
For this reason, pigs are frequently used to create
transgenic animals. Although they are not
phylogenetically the closest animals to humans, they are
rather similar in size, immune system and organ
structures. In addition, their progeny is quite numerous
and they have already had a successful clinical
application in heart valve transplantation and insulin
production (Cozzi and White, 1995).
A modern approach to create transgenic pigs is the
sperm-mediated gene transfer (SMGT). The technique
uses ejaculated sperm cells as vectors to transfer an
exogenous DNA sequence into eggs during fertilisation
(Lavitrano et al., 1997). The transgene was integrated
and transmitted to the following generations; h-DAF
resulted assembled correctly on pig cell membrane and it
conferred resistance to the complement-mediated lysis of
the pig cells (Lavitrano et al., 1997).
We have already demonstrated that this method
produces a high percentage of first generation human-
DAF (h-DAF) transgenic pigs (Cappello et al., 2000).
Moreover, we have also shown that h-DAF was strongly
expressed in specimens obtained from heart, lung,
kidney, aorta and skeletal muscle, not only in the first
generation but also in the following, with efficiency up
to 40% (Lazzareschi et al., 2000). The function of h-
DAF has now been assessed by an ex vivo experimental
model of perfusion. 
In this study, we evaluated the HAR phenomena in
isolated h-DAF transgenic pig hearts after perfusion with
human blood. We analysed anatomo-clinical features,
histological damage, ultrastructural alterations, h-DAF
expression and complement deposition, in order to verify
the protective role of h-DAF in this experimental model
and to better codify the spectrum of morphological
modifications following a heart xenograft simulation.
Materials and methods
Tissue sampling
Hearts were isolated from five adult h-DAF
transgenic pigs and six controls. The transgenic pigs,
obtained following the SMGT technique (Lavitrano et
al., 1997), belonged to the third generation. In previous
experiments we assessed the h-DAF expression by
immunoperoxidase on frozen skeletal muscle biopsy
(data not shown) to choose only strongly expressing h-
DAF transgenic pigs. Pigs were pre-anaesthetised with
pentothal, intubated, anaesthetised with isofluoran and
nitric protoxide and curarised with pavulon. After thorax
opening, the hearts were isolated and perfused with a
cold cardioplegic solution containing heparin and
subsequently jointed to an extra corporeal perfusion
system by aorta. The hearts of transgenic pigs and of
five controls were perfused with heparinized fresh
human blood (heterologous blood) at an output of 2
litres/min for 4 hours. One control pig heart was
perfused with its own blood (homologous blood). During
perfusion, haematic pH, by regulation of pO2 and pCO2,
and glycemia were maintained at physiological levels. A
transmitralic balloon monitored the coronary perfusion
pressure. The hearts were weighed before and after
perfusion and the weight was registered. After
perfusions, multiple biopsies from each ventricle and
from interventricular septum for traditional histological
examination were performed. Other biopsies, obtained
from the left ventricle, were processed for electron
microscopy analysis and frozen in liquid nitrogen for
immunohistochemistry and molecular biology. 
Morphological analysis 
Sections of formalin-fixed, paraffin-embedded
specimens were stained with hematoxylin and eosin to
evaluate the morphological status of the myocardium.
Oedema, necrosis, thrombosis, endothelial damage and
lymphocytic and plasmacellular infiltration were
semiquantitated, by two independent observers,
according to the tissue percentage involved in the
pathological process on 10 high power fields (HPF, x40)
(absent: -; less than 33% of tissue: +; 34-66%: ++; more
than 67%: +++). 
Electron microscopy
Ultrathin sections of 2,5% glutharaldehyde-fixed,
epon-embedded specimens were observed by a JEOL
1220 transmission electron microscope. Sarcomeral,
sarcotubular and mitochondrial damage was estimated
on the basis of damaged cell percentage in 5 meshes
(absent: -; less than 33% of cells: +; 34-66%: ++; more
than 67%: +++). This semi-quantitative score was
obtained by two independent observers.
Immunohistochemistry
Immunostaining by the avidin-biotin complex
method (LSAB2 kit peroxidase, DAKO Cat. No K0677)
was performed, using primary antibodies against h-DAF
(monoclonal mouse, 1:100, UBI, Cat. No 05-285),
human C3c complement (polyclonal rabbit, 1:100,
DAKO, Cat. No A0062) and isotype-matched control.
Aminoethilcarbazole was used as chromogen. The
results were semiquantitated by two expert observers, on
cell percentage presenting the antigens on 10 HPF
(absent: -; less than 33% of cell: +; 34-66%: ++; more
than 67%: +++).
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Preparation of tissue extracts
Fresh tissues from perfused pig hearts were
homogenized in lysis buffer (LB: 50mM Tris HCl pH
7.5, 150mM NaCl, 1% NP-40, 1mM EGTA), containing
protease inhibitors (Protease Inhibitor Cocktail Set III,
Calbiochem, Cat. No 539134), and centrifuged at 13,000
rpm for 10 minutes at 4 °C. The supernatant was
collected and the protein concentration was determined
using a colorimetric assay (DC Protein Assay, Biorad,
Cat. No. 5000116). 
Western blot analysis 
20 µg of total cell extracts in each lane and a protein
marker (Kaleidoscope prestained standard, Bio-Rad, Cat.
No 1610324) were separated by electrophoresis on
denaturing 10% polyacrylamide slab gel (SDS-PAGE)
and transferred to a nitrocellulose membrane (Nitrocell
Paper, Bio-Rad, Cat. No 1620115). After 1 hour at room
temperature (RT) with a blocking buffer (5% low-fat
dried milk in TBST: 50mM Tris-HCl pH 7.5, 150 mM
NaCl, 0,1% Tween-20) under gentle shaking, the
membrane was incubated with anti-h-DAF primary
antibody (monoclonal mouse, 1:300, UBI, Cat. No 05-
285) overnight at 4 °C.
After washings, the membrane was incubated with
HRP-conjugated secondary antibody (anti-mouse,
Pierce, 1:8000, Cat. No 31432) for 1 hour at RT with
shaking and the specific binding was detected using a
chemiluminescent substrate (SuperSignal West Pico
Chemiluminescent Substrate, Pierce, Cat. No 34080) for
autoradiography.
The same membrane was stripped with a stripping
buffer (Restore TM Western Blot Stripping Buffer,
Pierce, Cat. No 21059) and incubated with anti-human
C3c complement primary antibody (polyclonal rabbit,
1:500, DAKO, Cat. No A0062), following the
procedures described above (secondary antibody: anti-
rabbit, Pierce, 1:10000 Cat. No 31462).
Statistical analysis
Standard statistic analyses were employed to
calculate the means and the standard deviation (SD).
One-way analysis of variance was used to determine the
presence of significant differences within the data.
Differences between the means were regarded as
significant when a value of  p<0.05 was obtained.
Results
Anatomo-clinical results
After perfusion, the increase of coronary perfusion
pressure was 137±10% in heterologous blood-perfused
control hearts (HEBPCH), 54±16% in heterologous
blood-perfused transgenic hearts (HEBPTH), and 25%
in homologous blood-perfused control heart (HOBPCH)
(p<0.001) (Fig. 1). Moreover, heart weight increased
39.7±3.5% in HEBPCH, 21±3.6% in HEBPTH and 17%
in HOBPCH (p<0.005) (Fig. 1). Statistical analysis
revealed that the difference between HEBPCH and
HEBPTH was significant (p<0,05).
Histological data
All observed HEBPCH samples showed a moderate
interstitial oedema. In contrast, oedema in HEBPTH and
HOBPCH was negligible (Tab1e 1; Fig. 2, H,E).
Moreover, HEBPCH showed a severe endothelial
damage; the endothelial lamina was discontinuous,
compared to HEBPTH, in which the endothelium
resulted scarcely altered in an irrelevant number of small
vessels (Fig. 2, H,E inset). In addition, small vessels in
HEBPCH resulted abnormally dilated whereas
HOBPCH presented a normal endothelium. 
Furthermore, a low-moderate thrombosis was observed
in HEBPCH, often associated with capillary congestion.
These features were inconspicuous in HEBPTH and
absent in HOBPCH (Table 1). In addition, necrosis,
hypereosinophilia of myocytes, contraction band
formation and intercalated disc disruption were
uncommon features. Indeed, we noted a negligible
presence of these phenomena in three out of five
HEBPCH (Table 1). 
Finally, no lymphatic or plasma cellular infiltration
was present in any examined specimens (Table 1).
Electron microscopy
The myocardial fibres did not show any sarcomeral
or sarcotubular alteration in any observed specimens. In
contrast, mitochondrial damage was present in only two
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Fig. 1. Histograms showing the increment of coronary perfusion
pressure and heart weight in control and transgenic pig hearts.
HEBPCH: heterologous blood perfused control heart; HEBPTH:
heterologous blood perfused transgenic heart; HOBPCH: homologous
blood perfused control heart.
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Fig. 2. Light Microscopy (LM).
Oedema and necrosis are
evident in HEBPCH (4X); the
inset shows damage of
endothelium (x 40). HEBPTH
presents only a low pericellular
oedema (x 4); the inset shows an
unaltered endothelium in
arteriolae (x 40). A negligible
oedema is presents in HOBPCH
(4X); the inset shows a normal
endothelium (x 40). Trasmission
Electron Microscopy (TEM).
Damaged mitochondria in
HEBPCH (x 5000). HEBPTH and
HOBPCH show normal
sarcomeral and mitochondrial
status (x 5000). HEBPCH:
heterologous blood perfused
control heart; HEBPTH:
heterologous blood perfused
transgenic heart; HOBPCH:
homologous blood perfused
control heart
Table 1. Histologic evaluation of damages in HOBPCH, HEBPCH and HEBPTH. Damages are semiquantitated on four levels: -: absent, +: low; ++:
moderate; +++: severe, as described in Materials and Methods. 
PERICELLULAR ENDOTHELIAL THROMBOSIS NECROSIS MYOCYTES CONTRACTION LYMPHOCYTIC AND
EDEMA DAMAGE HYPEREOSINOPHILIA BANDS PLASMACELLULAR 
INFILTRATION
HOBPCH + - - - - - -
HEBPCH-1 ++ ++ + - - - -
HEBPCH-2 ++ +++ ++ + + + -
HEBPCH-3 + ++ ++ - - - -
HEBPCH-4 ++ +++ ++ + + + -
HEBPCH-5 ++ ++ + + + - -
HEBPTH-1 + + + - - - -
HEBPTH-2 + + - - - - -
HEBPTH-3 + - - - - - -
HEBPTH-4 + + + - - - -
HEBPTH-5 + + + - - - -
-: absent; +: low; ++: moderate; +++: strong.  HEBPCH: heterologous blood perfused control heart; HEBPTH: heterologous blood perfused transgenic
heart; HOBPCH: homologous blood perfused control heart.
of the HEBPCH (Table 2; Fig. 2, TEM). In particular,
mitochondria were swollen and showed disruption of the
crests . 
Immunohistochemistry
H-DAF was uniformly distributed in HEBPTH
myocardiocytes from subepicardium to subendocardium.
Particularly, h-DAF was mostly localized on the
plasmalemma of myocardiocytes, compared to the
scarce positivity found in the cytoplasm (Fig. 3, h-DAF).
In addition, h-DAF was strongly expressed in
endothelium of both endocardium and intraparietal
vessels. In contrast, the h-DAF expression was negative
in both myocardiocytes and endothelial cells of
HEBPCH and HOBPCH (Fig. 3, h-DAF). Moreover,
human C3c was abundantly deposited on plasmalemma
of HEBPCH endothelial and myocardial cells, while it
was scarcely present in HEBPTH and absent in
HOBPCH (Fig. 3, C3c). C3c absence in HEBPTH can
be strongly related to the presence of h-DAF. 
Western blot analysis
Anti-h-DAF antibody recognised specifically the
transgenic h-DAF protein (63 KDa) in HEBPTH and did
not cross-react with any other protein present in
HEBPCH and HOBPCH (Fig. 4a). Moreover, the human
C3c (70 KDa) (Fig. 4b) accumulated only in HEBPCH,
confirming that h-DAF inhibited the complement
activation in HEBPTH. Therefore, these data confirmed
the immunohistochemical observations.  
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Table 2. Immunohistochemistry results and TEM evaluation of damages in HOBPCH, HEBPCH and HEBPTH. Antibody expression and damage
evaluation are semiquantitated on four levels: -: absent, +: low; ++: moderate; +++: severe as described in Materials and Methods. 
DAF EXPRESSION C3 DEPOSITION SARCOMERAL SARCOTUBULAR MITOCHONDRIAL
DAMAGES DAMAGES DAMAGES
HOBPCH - - - - -
HEBPCH-1 - ++ - - -
HEBPCH-2 - +++ - -
HEBPCH-3 - +++ - - -
HEBPCH-4 - +++ - ++
HEBPCH-5 - ++ - - +
HEBPTH-1 ++ ++ - - -
HEBPTH-2 +++ + - - -
HEBPTH-3 +++ + - - -
HEBPTH-4 +++ + - - -
HEBPTH-5 ++ + - - -
-: absent; +: low; ++: moderate; +++: strong. HEBPCH: heterologous blood perfused control heart; HEBPTH: heterologous blood perfused transgenic
heart; HOBPCH: homologous blood perfused control heart.
Fig. 3. Immunohistochemistry.
H-DAF: Photomicrographs
showing strong presence of
immunostaining for h-DAF in
HEBPTH and absence in
HEBPCH and HOBPCH (x
10). C3c: immunostained
sections showing C3c
presence in HEBPCH and
absence in HEBPTH and
HOBPCH (x 10). (EBPCH:
heterologous blood perfused
control heart; HEBPTH:
heterologous blood perfused
transgenic heart; HOBPCH:
homologous blood perfused
control heart.
Discussion
Until a few years ago, HAR was considered as an
absolute barrier to xenografts between phylogenetically
distant species. Indeed, Lexer et al. (1996) hemoperfused
eight freshly excised pig hearts in baboons in vivo,
finding that six of them ceased their function after a
mean period of 90 minutes, while only two continued
functioning for the 4-hour study period. On microscopic
examination, seven hearts including one that continued
beating, presented histopathological features of HAR,
with a strong deposition of C3 on the myocardium. HAR
was normally detected within a few hours from the
xenograft and was considered as the inevitable
consequence of it. Moreover, in another experiment, pig
livers perfused for 9 hours with human blood showed
that, despite biochemically and histologically confirmed
tissue injury, graft viability was well-maintained in
xenoperfusion even without immunological
manipulations (Terajima et al., 1996).
The initiating factor of pig organ HAR by human or
non-human primates is the presence of preformed
antibodies in the host (Cooper et al., 1994). These
xenoantibodies recognise the terminal alpha-1,3-
galactose disaccharide present on pig endothelium.
Moreover, the species incompatibility between human
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Fig. 4. Western blotting of
extracted proteins from
HOBPCH; HEBPCH and
HEBPTH. (a) 10% SDS-
PAGE and immunoblotting
of h-DAF (63 KDa, lane 7-
11). H-DAF is present only
in HEBPTH. (b) 10% SDS-
PAGE and immunoblotting
of C3c (70 KDa, lane 2-6).
C3c is present only in
HEBPCH. HEBPCH:
heterologous blood
perfused control heart;
HEBPTH: heterologous
blood perfused transgenic
heart; HOBPCH:
homologous blood
perfused control heart.
and porcine complement regulatory proteins is also a
further element for HAR (van Denderen et al., 1997). 
The employment of immunological techniques and
the recent development of genetic engineering have
permitted the extension of xenograft survival for a
longer period after transplantation. For example,
immunoabsorption techniques for anti-pig antibody
using immunoaffinity columns permitted the
prolongation of the survival of xenografted kidneys
without HAR up to 13 days (Sachs, 1994). Moreover,
the efficacy of highly selective immunoadsorption
columns to deplete xenoreactive human anti-porcine
antibodies, before ex vivo liver perfusion, resulted in an
effective approach for delaying antibody-mediated
xenogeneic HAR (Kroshus et al., 1995; Pascher et al.,
1997). In addition, h-DAF expression combined with
alpha-1,3-galactosyltransferase in transgenic
transplanted splenocytes was a protection from
complement-mediated injury in a model of HAR in mice
(van Denderen et al., 1997). 
The depletion of complement using a highly purified
form of cobra-venom factor also significantly extended
the cardiac xenograft survival in both guinea pig-to-rat
and pig-to-baboon animal models (Leventhal, 1993).
Finally, endogenously-expressed complement-regulatory
molecules, like CD59 and CD46 on pig endothelium
resulted in playing an important role in the protection
against HAR in in vitro (van der Berg et al., 2000) and
ex vivo (Perez de la Lastra et al., 1999) models. 
In addition, transgenic organs expressing high levels
of human complement regulatory proteins alleviated the
humoral immunological barriers currently blocking
xenograft, being able to contribute to the control of
complement activation in many organs (McCurry et al.,
1995b; Byrne et al., 1997)
Numerous works showed that h-DAF transgene
combined with maintenance of immunosuppression is
able to support life for a prolonged period in porcine
cardiac xenografts in non-human primates (Waterworth
et al., 1998; Vial et al., 2000). Moreover, h-DAF
expression increased heart transplant survival in rat- (or
mouse-) to-primate models of xenograft (Cowan et al.,
1998; Charreau et al., 1999). In addition, h-DAF
transgenic pig livers transplanted in five baboons
resulted protected from HAR for 4-8 days (Ramirez et
al., 2000).
The utilisation of pig organs in xenograft has
prompted the purification and characterisation of some
porcine complement inhibitors (van den Berg 1995,
1997). Recently, the cloning of cDNAs encoding
multiple isoforms of the pig analogue to h-DAF was
reported (Perez de la Lastra et al., 2000). Pig DAF was
expressed in a wide range of tissues and on all
circulating cells and it was transmembrane-anchored on
erythrocytes, but its regulatory activity on the
complement pathway is actually the object of further
studies.
The extra-corporeal perfusion model employed in
this study resulted highly efficient to simulate a
xenograft, as demonstrated by the analysed controls
(HOBPCH and HEBPCH).
We utilised heparinized fresh human blood of O
hemogroup. The choice of which human blood group to
use for xenoperfusions is not important. In fact, despite
human type-A and -H blood antigens being present in
both porcine exocrine secretions (Watkins, 1972) and
erythrocytes (Sako et al., 1990), they are not detectable
on vascular endothelium; the latter suggests that they are
not involved in the HAR, although the pig A antigen can
induce an immune response in O or B blood group
recipients (Oriol et al., 1994).
Endothelial cell disruption is one of the most
indicative features of HAR phenomena and its presence
is considered strictly specific of this pathology (Rose et
al., 1991). Indeed, immediately after the
revascularisation of xenotransplanted organs,
complement activation triggers the endothelial cell lysis,
with the following thrombosis and tissue necrosis
(Dalmasso et al., 1991); normally, HAR is observed
within a few hours.
We found a conspicuous number of damaged
endothelial cells only in HEBPCH. We considered this
endothelial alteration due to the high titres of natural
antibodies reacting with the carbohydrate residues
present in porcine vascular endothelial cells and
activating the complement cascade (Neethling et al.,
1994). Moreover, we considered the endothelial damage
as the triggering factor of oedema, which is responsible
for both coronary perfusion pressure and heart weight
increase. In addition, our results showed that the
presence of h-DAF on both endothelial and myocardial
cell surface significantly reduced the C3c deposition in
transgenic hearts, protecting them from HAR in all five
cases for the observed period of four hours. In contrast,
HEBPCH showed C3c deposition and HAR phenomena.
This evidence had already been demonstrated in human
plasma-perfused CD55/CD59 transgenic mouse hearts,
in which immunopathological analysis of serial biopsies
revealed the inhibition of complement activation (Byrne
et al., 1995).
Therefore, the anatomo-clinical features reported in
HEBPCH permitted us to diagnose the HAR (Aretz
1999), even if they did not present a significant
lymphoplasmacellular infiltration. The latter might
concurrently occur, although remaining focal and mild.
In our cases, its absence could be due to the fact that
hearts were perfused for only four hours, a too short time
to activate the biological events necessary for the
leukocyte migration (Janeway and Travers, 1997b).
Moreover, the absence of cellular lymphoid infiltrate had
already been reported in 551 sequential endomyocardial
biopsies from 36 consecutive cardiac allografts in the
early period (3 weeks) after transplantation (Hammond.
1989). 
We concluded that the h-DAF expression in
HEBPTH protected them from HAR. These results are
in agreement with what has already been shown in the
literature, using different approaches. Moreover, these
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data suggest that in a combined approach with
immunoabsorption, immunosuppression and genetic
engineering techniques, the presence of complement-
regulating proteins (as h-DAF) in transgenic hearts
should be considered as a useful means to alleviate the
complement barrier upon graft of this highly
vascularised organ into human, as well as to
considerably extend the survival of transplanted organs.
A detailed knowledge of morphological modifications
following transgenic xenograft will permit the exclusion
of HAR phoenomena in bioptic specimens after hours or
days from transplantation.
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